LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,410 | -6.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,500 | +28.2% | 1,000 | 0.0% | 0.00% | – |
| Q4 2022 | $1,170 | -99.9% | 1,000 | 0.0% | 0.00% | – |
| Q3 2022 | $1,130,000 | -28.5% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $1,580,000 | +2.6% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,540,000 | -37.1% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $2,450,000 | -2.8% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $2,520,000 | -11.6% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $2,850,000 | +21.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $2,350,000 | +33.5% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,760,000 | +87.8% | 1,000 | 0.0% | 0.00% | – |
| Q3 2020 | $937,000 | +7.7% | 1,000 | 0.0% | 0.00% | – |
| Q2 2020 | $870,000 | +86900.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $2,000 | +100.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $1,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
| Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
| Raffles Associates | 93,590 | $236,000 | 0.22% |
| Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
| DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
| Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
| Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
| Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |